Overall rank by patents
#1,153
Across all tracked assignees
USPTO PatentsView assignee record - 368 granted patents across 43 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
The verdict
St. holds 368 US patents across 43 technology areas, rank #1,153 of 50,000 tracked assignees.
St. Jude Medical, Atrial Fibrillation Division, Inc. has been granted 368 US utility patents between 2015 and 2025, placing St. Jude Medical, Atrial Fibrillation Division, Inc. at rank #1,153 across all assignees tracked by PlainPatent. This portfolio spans 43 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.2 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, St. Jude Medical, Atrial Fibrillation Division, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, St. sits between MARS, Incorporated (369 patents, rank #1,149) and Enplas Corporation (367 patents, rank #1,157) - the closest US assignees by grant volume. The composite Innovation Score of 56.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 95 grants, compared with 273 in the 2015–2019 window, a -65% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. St. Jude Medical, Atrial Fibrillation Division, Inc.'s 17.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 43 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark St. Jude Medical, Atrial Fibrillation Division, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
MARS, INCORPORATED
369 patents
Oakley, Inc.
369 patents
GULFSTREAM AEROSPACE CORPORATION
368 patents
KT&G CORPORATION
368 patents
TRUSTEES OF DARTMOUTH COLLEGE
368 patents
YEDA RESEARCH AND DEVELOPMENT CO. LTD.
368 patents
St. Jude Medical, Atrial Fibrillation Division, Inc.
368 patents
Convida Wireless, LLC
367 patents
Enplas Corporation
367 patents
What this shows St. holds 368 patents at rank #1,153, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #1,153 in granted patent volume.
Other assignees with the most granted patents in St's primary technology class.
St.'s Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
56 Top 6% higher than 94% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 60 | 16.3% |
| 2016 | 59 | 16.0% |
| 2017 | 60 | 16.3% |
| 2018 | 50 | 13.6% |
| 2019 | 44 | 12.0% |
| 2020 | 30 | 8.2% |
| 2021 | 25 | 6.8% |
| 2022 | 17 | 4.6% |
| 2023 | 12 | 3.3% |
| 2024 | 5 | 1.4% |
| 2025 | 6 | 1.6% |
Top 15 of 43 technology areas
Overall rank by patents
#1,153
Across all tracked assignees
56.2 out of 100
How to use this portfolio
St.'s 368 grants land it in the top 6% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.